Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
暂无分享,去创建一个
E. V. Van Allen | C. Drake | J. Allison | S. Hu-Lieskovan | C. M. Fares | Hu-Lieskovan Siwen | C. Fares
[1] M. Najafi,et al. Contribution of regulatory T cells to cancer: A review , 2018, Journal of cellular physiology.
[2] M. Hellmann,et al. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] A. Tafreshi,et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[4] J. Sicklick,et al. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors , 2018, JAMA oncology.
[5] S. Yentz,et al. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy , 2018, BioDrugs.
[6] M. Kudo,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.
[7] L. Emens,et al. Targeting adenosine for cancer immunotherapy , 2018, Journal of Immunotherapy for Cancer.
[8] Federico Cappuzzo,et al. Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.
[9] A. Hauschild,et al. PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma , 2018, The New England journal of medicine.
[10] J. Schellens,et al. Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study. , 2018 .
[11] Christopher M. Jackson,et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM , 2018, Oncoimmunology.
[12] P. Philip,et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial , 2018, JAMA oncology.
[13] G. Mills,et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade , 2018, Nature Medicine.
[14] S. Novello,et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[15] B. Helmink,et al. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. , 2018, Cancer cell.
[16] S. Niclou,et al. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. , 2018, Blood.
[17] P. Norlén,et al. Bispecific antibodies in cancer immunotherapy , 2018, Therapeutic advances in vaccines and immunotherapy.
[18] M. Kloor,et al. Complex pattern of immune evasion in MSI colorectal cancer , 2018, Oncoimmunology.
[19] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[20] Y. Lou,et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges , 2018, Journal of Hematology & Oncology.
[21] Dai Fukumura,et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.
[22] Steven H. Lin,et al. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions , 2018, Front. Pharmacol..
[23] P. Hegde,et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.
[24] Mark W. Ball,et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma , 2018, Science.
[25] Henry W. Long,et al. A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing , 2018, Science.
[26] Camille Stephan-Otto Attolini,et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.
[27] R. Bourgon,et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.
[28] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[29] E. Le Chatelier,et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.
[30] Riyue Bao,et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.
[31] Vinay Prasad,et al. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. , 2017, JAMA oncology.
[32] E. Jaffee,et al. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.
[33] Ju-Han Lee,et al. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma , 2017, Scientific Reports.
[34] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[35] Nicholas J. Vogelzang,et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study , 2017, JAMA oncology.
[36] D. Schadendorf,et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.
[37] Tarek Mekhail,et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[38] J. Desai,et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.
[39] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[40] John G. Doench,et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target , 2017, Nature.
[41] Charles H. Yoon,et al. An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.
[42] M. Kudo,et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.
[43] A. Eggermont,et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] E. Schmidt,et al. ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma. , 2017 .
[45] A. Mai,et al. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy , 2017, Clinical Epigenetics.
[46] Jeffrey E. Lee,et al. Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. , 2017 .
[47] Christina S. Leslie,et al. Chromatin states define tumor-specific T cell dysfunction and reprogramming , 2017, Nature.
[48] Robert Damoiseaux,et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.
[49] Daniela Massi,et al. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. , 2017, Seminars in cancer biology.
[50] L. Apetoh,et al. Rationale for stimulator of interferon genes-targeted cancer immunotherapy. , 2017, European journal of cancer.
[51] L. Zitvogel,et al. Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. , 2017 .
[52] I. Wistuba,et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer , 2017, Nature Medicine.
[53] J. Yokota,et al. Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition , 2017, Clinical Cancer Research.
[54] A. Hoffmann,et al. Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells , 2017, Proceedings of the National Academy of Sciences.
[55] E. Plimack,et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.
[56] C. Zahnow,et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.
[57] P. A. Futreal,et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance , 2017, Science Translational Medicine.
[58] David M. Thomas,et al. IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting , 2017, Nature Communications.
[59] S. Carter,et al. Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma , 2017, Immunity.
[60] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.
[61] T. Graeber,et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. , 2017, Cancer discovery.
[62] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.
[63] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.
[64] R. Ferris,et al. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer , 2017, Oncoimmunology.
[65] Todd M. Allen,et al. The epigenetic landscape of T cell exhaustion , 2016, Science.
[66] S. Berger,et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade , 2016, Science.
[67] H. Ishwaran,et al. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade , 2016, Cell.
[68] J. Luke,et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.
[69] J. Kutok,et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells , 2016, Nature.
[70] K. Odunsi,et al. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer , 2016, Oncoimmunology.
[71] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[72] J. Wargo,et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.
[73] G. Linette,et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[74] Philippe Foubert,et al. PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.
[75] M. Boutros,et al. Wnt signaling in cancer , 2016, Oncogene.
[76] K. Savage,et al. Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study , 2016, The Lancet. Oncology.
[77] Suzanne F. Jones,et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma , 2016, Nature Communications.
[78] E. Elkord,et al. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting , 2016, Vaccines.
[79] D. Schadendorf,et al. Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. , 2016, Cancer research.
[80] T. Chan,et al. The role of neoantigens in response to immune checkpoint blockade. , 2016, International immunology.
[81] L. Chin,et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.
[82] T. Graeber,et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.
[83] R. Hollingsworth,et al. Targeting CD73 in the tumor microenvironment with MEDI9447 , 2016, Oncoimmunology.
[84] M. Vetizou,et al. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. , 2016, Immunity.
[85] J. Malvehy,et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. , 2016 .
[86] J. Desai,et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). , 2016 .
[87] Ana C Anderson,et al. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.
[88] Drew M. Pardoll,et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. , 2016, The New England journal of medicine.
[89] Eric S. Lander,et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma , 2016, Cell reports.
[90] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[91] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.
[92] M. Belvin,et al. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. , 2016, Immunity.
[93] Shohei Koyama,et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.
[94] Lauren L. Ritterhouse,et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer , 2016, Oncotarget.
[95] J. McQuade,et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.
[96] Dana Pe'er,et al. PD-1 Blockade Expands Intratumoral Memory T Cells , 2016, Cancer Immunology Research.
[97] Yi-long Wu,et al. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy , 2016, Tumor Biology.
[98] S. Demaria,et al. Role of Local Radiation Therapy in Cancer Immunotherapy. , 2015, JAMA oncology.
[99] Jason B. Williams,et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.
[100] F. Ginhoux,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.
[101] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[102] S. Mallal,et al. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors , 2015, Clinical Cancer Research.
[103] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[104] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[105] H. Kohrt,et al. T-cell–based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition , 2015, Cancer Immunology Research.
[106] P. Beavis,et al. Indian breast cancer -The shifting paradigms and finding Indian solutions!! , 2015 .
[107] L. Zitvogel,et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. , 2015, Cancer Research.
[108] Kathleen R. Cho,et al. Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy , 2015, Nature.
[109] M. Scott Lucia,et al. Paucity of PD-L1 Expression in Prostate Cancer: Innate and Adaptive Immune Resistance , 2015, Prostate Cancer and Prostatic Disease.
[110] Jens Schreiner,et al. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors , 2015, Cancer Immunology Research.
[111] Wei Zhou,et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.
[112] G. Freeman,et al. Combination cancer immunotherapy and new immunomodulatory targets , 2015, Nature Reviews Drug Discovery.
[113] E. Wherry,et al. Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.
[114] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[115] D. Linehan,et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.
[116] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[117] Antoni Ribas,et al. Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.
[118] G. Crabtree,et al. Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics , 2015, Science Advances.
[119] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[120] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[121] G. Linette,et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. , 2015 .
[122] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[123] S. Loi,et al. CD73: A potential biomarker for anti-PD-1 therapy , 2015, Oncoimmunology.
[124] R. Jain,et al. CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice , 2015, Hepatology.
[125] Brian Ruffell,et al. Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.
[126] C. Drake,et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.
[127] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[128] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[129] D. Fearon,et al. T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.
[130] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[131] T. Graeber,et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma , 2015, Science Translational Medicine.
[132] H. Yagita,et al. Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment , 2015, PloS one.
[133] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[134] E. Tartour,et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors , 2015, The Journal of experimental medicine.
[135] L. Tsvetkov,et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4 , 2015, Clinical Cancer Research.
[136] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[137] C. Horak,et al. Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma , 2014, Clinical Cancer Research.
[138] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[139] L. Dwyer-Nield,et al. Depletion of Tumor-Associated Macrophages Slows the Growth of Chemically Induced Mouse Lung Adenocarcinomas , 2014, Front. Immunol..
[140] M. Seshadri,et al. CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells , 2014, The Journal of Immunology.
[141] Youwen Zhou,et al. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. , 2014, The Journal of investigative dermatology.
[142] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[143] P. Pandolfi,et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. , 2014, Cell reports.
[144] N. Itano,et al. Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment , 2014, Cancers.
[145] K. Kinzler,et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Journal of Immunotherapy for Cancer.
[146] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[147] R. Schwabe,et al. The Yin and Yang of Toll-like receptors in cancer , 2014, Oncogene.
[148] Amber J. Giles,et al. Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy , 2014, Science Translational Medicine.
[149] G. Coukos,et al. Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.
[150] G. Prendergast,et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer , 2014, Cancer Immunology, Immunotherapy.
[151] C. Meyer,et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab , 2014, Cancer Immunology, Immunotherapy.
[152] H. Koblish,et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.
[153] R. Weichselbaum,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.
[154] D. Shin,et al. CTLA-4 Blockade Enhances Antitumor Immunity of Intratumoral Injection of Immature Dendritic Cells into Irradiated Tumor in a Mouse Colon Cancer Model , 2014, Journal of immunotherapy.
[155] D. Farber,et al. Human memory T cells: generation, compartmentalization and homeostasis , 2013, Nature Reviews Immunology.
[156] J. Karbach,et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans , 2013, Proceedings of the National Academy of Sciences.
[157] C. Roberts,et al. Molecular Pathways Molecular Pathways : SWI / SNF ( BAF ) Complexes Are Frequently Mutated in Cancer — Mechanisms and Potential Therapeutic Insights , 2013 .
[158] H. Schreiber,et al. Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.
[159] M. Smyth,et al. Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs , 2013, Clinical Cancer Research.
[160] J. Wolchok,et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.
[161] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[162] J. Wolchok,et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.
[163] B. Ammori,et al. Myeloid‐derived suppressor cells in cancer: recent progress and prospects , 2013, Immunology and cell biology.
[164] G. Freeman,et al. Strength of PD-1 signaling differentially affects T-cell effector functions , 2013, Proceedings of the National Academy of Sciences.
[165] D. Munn,et al. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. , 2013, Trends in immunology.
[166] K. Flaherty,et al. BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice , 2012, Clinical Cancer Research.
[167] W. Wick,et al. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. , 2012, Cancer research.
[168] James J. Campbell,et al. Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells , 2012, Molecular Cancer Therapeutics.
[169] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[170] C. Drake,et al. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.
[171] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[172] Peter Vogel,et al. Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .
[173] Bin Zhang. CD73 promotes tumor growth and metastasis , 2012, Oncoimmunology.
[174] E. Wherry. T cell exhaustion , 2011, Nature Immunology.
[175] A. Rudensky,et al. Regulatory T cells and Foxp3 , 2011, Immunological reviews.
[176] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[177] Laurence Zitvogel,et al. Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.
[178] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[179] H. Harmsen,et al. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects , 2010, British Journal of Nutrition.
[180] S. Chatterjee,et al. Combination of CTL‐associated Antigen‐4 Blockade and Depletion of CD25+ Regulatory T Cells Enhance Tumour Immunity of Dendritic Cell‐based Vaccine in a Mouse Model of Colon Cancer , 2010, Scandinavian journal of immunology.
[181] A. Darabi,et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy , 2009, Cancer Immunology, Immunotherapy.
[182] Xi He,et al. Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.
[183] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[184] J. Kohlmeier,et al. Migration, maintenance and recall of memory T cells in peripheral tissues , 2009, Nature Reviews Immunology.
[185] J. Wolchok,et al. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. , 2008, The oncologist.
[186] G. Freeman,et al. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade , 2008, Proceedings of the National Academy of Sciences.
[187] R. Parsons,et al. The role of PTEN signaling perturbations in cancer and in targeted therapy , 2008, Oncogene.
[188] T. Nomura,et al. Regulatory T Cells and Immune Tolerance , 2008, Cell.
[189] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[190] D. Carbone,et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. , 2008, Cancer cell.
[191] E. Wherry,et al. CD8 T cell dysfunction during chronic viral infection. , 2007, Current opinion in immunology.
[192] O. Rath,et al. MAP kinase signalling pathways in cancer , 2007, Oncogene.
[193] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[194] T. Eberlein,et al. Depletion of CD4+CD25+ Regulatory T Cells Promotes a Tumor-Specific Immune Response in Pancreas Cancer–Bearing Mice , 2006, Annals of Surgical Oncology.
[195] S. Quezada,et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. , 2006, The Journal of clinical investigation.
[196] B. Fingleton,et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.
[197] David M. Conrad,et al. Adenosine Acts through A2 Receptors to Inhibit IL-2-Induced Tyrosine Phosphorylation of STAT5 in T Lymphocytes: Role of Cyclic Adenosine 3′,5′-Monophosphate and Phosphatases1 , 2004, The Journal of Immunology.
[198] R. Schreiber,et al. The three Es of cancer immunoediting. , 2004, Annual review of immunology.
[199] Manfred Thiel,et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. , 2004, Annual review of immunology.
[200] J. Allison,et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 , 2003, Nature Immunology.
[201] D. Carbone,et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. , 2003, Blood.
[202] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[203] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[204] G. Zhu,et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.
[205] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[206] J. Allison,et al. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.
[207] T. Honjo,et al. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.
[208] F. Denizot,et al. A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.
[209] J. Blay,et al. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial , 2018, JAMA oncology.
[210] A. Ravaud,et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. , 2018, The Lancet. Oncology.
[211] Mohd Feroz Mohd Omar,et al. P2.01-058 Mutational Features Associated with Immunoreactivity in Non-Small Cell Lung Cancer: Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy , 2017 .
[212] A. Ribas,et al. New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone , 2017, Cancer journal.
[213] M. Moser. Regulation of Th1/Th2 development by antigen-presenting cells in vivo. , 2001, Immunobiology.
[214] U. Boehm,et al. Cellular responses to interferon-gamma. , 1997, Annual review of immunology.